Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer.

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test.Please watch the video at Investors.com - The Cell Therapy Market Is ...

The analyst from Canaccord Genuity noted Guardant Health (NASDAQ:GH)'s extensive experience in blood-based cancer detection ...

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from ...

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...

Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated ...

The drugs treat prostate, breast and blood cancers. About 80,000 people with Medicare Part D coverage used them in a one-year ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...